

Benefits of Collaboration

Reduction

of

Risk

Enhanced Regulatory Compliance

Collaboration creates an opportunity to go beyond basic compliance by also addressing ethical and regulatory challenges. These include working together to develop alternative testing methodologies to reduce the use of animals in testing as well as improve safety-related attrition rates. By collaborating on these issues, stakeholders can collectively enhance the ethical and regulatory aspects of drug development while improving the overall process

Shared Expertise & Resources

Sharing of expertise and resources between stakeholders allows investors to have a direct involvement in the critical "Go/NoGo" decision-making based on the *in vivo* PoC data

Reduced Redundancy

Sharing of data and resources avoids duplication of effort and keeps all parties focused on advancing the drug development programme more efficiently

Accelerated Drug Development

By working together, stakeholders can identify and address challenges more quickly, leading to faster development and commercialisation of drug candidates

Improved Safety & Efficacy

المُنا

In addition to data on the safety and efficacy of drug candidates, *in vivo* toxicology testing labs provide valuable experience, adding further support to decision-making and reducing the risk of later failure